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6 ABSTRACT: Enantiopure 3-carboxamide-1,4-benzodiazepin-
7 5-ones were synthesized via the Ugi reaction followed by the
8 Staudinger/aza-Wittig or reduction reactions in only two steps.
9 A complete reversal of diastereoselectivity was achieved
10 depending on the cyclization methodology employed. The
11 diﬀerent orientation of the C3 substituent in our 3-substituted
12 1,4-benzodiazepin-5-ones with respect to the most studied 1,4-
13 benzodiazepin-2-ones makes them complementary in the
14 development of new drugs because the primary source of binding selectivity of 1,4-benzodiazepines is the selective recognition
15 of ligand conformations by the receptor.
16 Benzodiazepines are known as medicinally and pharma-17 ceutically important compounds which present selective
18 activities against a diverse array of biological targets. Besides
19 their properties as psychotropic drugs (anxiolytic,1 sedative,2 or
20 anticonvulsant agents3), other non-psychotropic biological
21 activities have been reported such as anti-HIV properties,4
22 antitumor antibiotics,5 and antimalarial6 or anticancer agents.7
23 Most of these benzodiazepines have in their structure one or
24 more stereogenic units,8 and even though legislative, economic,
25 and ecological pressure for the marketing of chiral molecules as
26 pure enantiomers9 has stimulated the development of cost-
27 eﬀective methods for the manufacture of enantiomerically pure
28 compounds, the stereoselective synthesis of benzodiazepines
29 has received little attention.10 The methods developed for the
30 construction of chiral benzodiazepines usually imply the
31 synthesis and resolution of racemic mixtures11 or the
32 introduction of stereogenic units by using α-amino acids from
33 the chiral pool.12
34 In previous papers, we have reported the synthesis of a new
35 family of racemic 1,4-benzodiazepines from diﬀerent Ugi/
36 cyclization sequences13 in which a new stereogenic center at the
37 C3-position was generated. Interestingly, unlike the 1,4-
38 benzodiazepin-2-ones possessing a chiral center at the C3
39 carbon, where the conformational equilibrium was shifted
40 toward the conformer having the larger substituent in the
41 pseudoequatorial position,14 the crystal X-ray analysis of our
42 1,4-benzodiazepin-5-ones13a showed that the preferred con-
43 formation for each enantiomer was that in which the
44 substituent in C3, the amide group derived from the isocyanide
45 component in the Ugi reaction, was pseudoaxially oriented,
46 probably because of a reduced steric hindrance between this
47 group and the N4-benzyl and C2-phenyl groups.15 This, in turn,
48 restricts the conformational equilibrium in the diazepine ring,
49 and consequently, the 3S stereoisomers adopt an M-
50 conformation and the 3R stereoisomers a P-conformation
f1 51 (Figure 1).
52The diﬀerent orientation of the larger substituent in our 1,4-
53benzodiazepin-5-ones with respect to the most studied 1,4-
54benzodiazepin-2-ones makes them complementary in the
55development of new drugs, as the four variations of the
56benzodiazepine scaﬀold combining the ring conformation and
57the orientation of the larger substituent in C316 could be
58controlled according to the family chosen. It has been
59suggested that the primary source of 1,4-benzodiazepine’s
60binding selectivity is the selective recognition of ligand
61conformations by the receptor.17 Consequently, by controlling
62the conﬁguration at C3 of these constrained benzodiazepines,
63we could control their conformation and therefore their
64activity. In this way, we found selective ﬁtting of our
65constrained benzodiazepines with diﬀerent β-turn motifs
66depending on their conformation and hence on the C3
67conﬁguration. Thus the 3R enantiomer superimposes well on
68the two central amino acid backbones of type I δ-antigen and
69 f2type II′ erabutoxin B (Figure 2), while the 3S enantiomer
70 f3perfectly ﬁts with the β-turn motifs of type I′ of acetyl CoA
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f3 71 carboxylase and type II of LDL receptor module 5 (Figure
f3 72 3).13a
73 Due to the relevance of this behavior, we thought about
74 developing the stereoselective synthesis of 3H-benzo[e][1,4]-
75 diazepin-5(4H)-ones. To that end, we relied on the
76 tautomerism observed in our previously described strategies.
77 On the one hand, the Ugi α-amido-β-ketoamide intermediates
78 obtained by these methodologies were exclusively in the enol
79form with no trace of the keto tautomer observed.13a On the
80other hand, when an oxo group was present at the 5-position in
81the 3H-benzo[e][1,4]diazepine system, the imine tautomer was
82the only form observed.13b Thus, although a new stereogenic
83center was usually generated in the Ugi reaction, the preferred
84enol form obtained using these methodologies would prevent
85its formation in this stage, leading to prochiral sp2 carbons. This
86constitutes an advantage because the stereoselectivity in the Ugi
87reaction is usually poor.11c Meanwhile, the preferred imine
88tautomer in the 3H-benzo[e][1,4]diazepin-5(4H)-ones gen-
89erated in the second stage would lead to stereogenic centers in
90the C3-position so that generation could be controlled in the
91cyclization step.
92Therefore, we tried the stereoselective synthesis of our
93benzodiazepines using commercially available enantiopure (S)-
94(−)-α-methylbenzyl amine 4 as the chiral component. The
95chosen Ugi/cyclization strategy determined the nature of the
96carboxylic acid used in the Ugi reaction. In this way, some 2-
97azidobenzoic acids (1a−d) synthesized from the corresponding
98anthranilic acid derivative and sodium azide18 were used in the
99Ugi/Staudinger/aza-Wittig sequence, while commercially avail-
100able 2-nitrobenzoic acid derivatives (1e−g) were used in the
101 s1Ugi/reduction cyclization sequence (Scheme 1).
102The Ugi reaction was carried out in a similar way in both
103sequences following the usual procedure.19 Therefore, the
104corresponding imine was preformed by mixing the (S)-(−)-α-
105methylbenzyl amine 420 (1 equiv) with a solution of
106arylglyoxals21 3a−c (1 equiv) in methanol. Alkyl isocyanides
1072a,b (1 equiv) and the corresponding benzoic acids 1a−g (1
108equiv) were then added to the imine solution, and the mixture
109was stirred at room temperature for one day until precipitation
110of Ugi products. Filtration of solids aﬀorded the Ugi adducts
111(azides 5a−d and nitro derivatives 6a−f). As expected, the only
112 t1tautomer observed by NMR spectra of these Ugi adducts was
Figure 2. Superimposition of the 3R enantiomer to a peptide
backbone of (a) type I β and (b) type II′ β-turn motifs.
Figure 3. Superimposition of the 3S enantiomer to a peptide backbone
of (a) type I′ β and (b) type II β-turn motifs.
Scheme 1. Syntheses of Benzodiazepines from 2-Azides 1a−d and 2-Nitrobenzoic Acids 1e−g
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t1 113 the enol form (as a conformer mixture) (Scheme 1 and Table
t1 114 1).
115 The obtained Ugi adducts were then subjected to the
116 appropriate conditions in order to achieve the cyclization to
117 benzodiazepines. Thus, the chiral azide Ugi adducts 5a−d (1
118 equiv) were treated under optimized Staudinger/aza-Wittig
119 conditions13a using triphenylphosphine (1.5 equiv) under a
120 nitrogen atmosphere in toluene for 24 h at room temperature.
121 Conversely, chiral nitro Ugi adducts 6a−f were treated in the
122 optimized chemical conditions found for the achiral sub-
123 strates,13b by using stannous chloride (10 equiv) as reductant in
124 the presence of hydrochloric acid (3 equiv) in ethanol for 45
125 min at reﬂux. A range of diﬀerent substituents participated
126 eﬃciently in these reactions, yielding the desired 1,4-
127 benzodiazepin-5-ones 7a−i with high chemical yields. These
128 synthetic methods easily led to C7/C8-substituted 1,4-
129 benzodiazepines (R1, R2: NO2, Cl, I), which could be easily
130 functionalized to generate chemical diversity (Scheme 1 and
131 Table 1).
132 From a stereochemical point of view, as it was expected that
133 the imine was the only observed tautomer, and therefore, a new
134 stereogenic center was generated in the cyclization step. The
135 cyclization took place in a stereoselective way, with moderate to
136 excellent diastereoselectivity, as determined by 1H NMR
137 analysis of the crude reaction mixtures22 (Table 1). The
138 diastereomers could be easily separated by column chromatog-
139 raphy or recrystallization, aﬀording enantiopure benzodiaze-
140 pines.
141 The degree of diastereoselectivity achieved in the reduction/
142 intramolecular cyclization tandem reaction from nitro-Ugi
143 adducts was higher than that achieved with the Staudinger/
144 aza-Wittig methodology from the azide derivatives (Table 1,
145 entry 5 vs 1), with almost complete diastereoselectivity for the
146 former (Table 1, entries 5−10). Although these stereochemical
147 results are highly positive, a much more remarkable aspect is
148 the sense of stereoselectivity achieved in each case because a
149 complete reversal of diastereoselectivity was observed depend-
150 ing on the cyclization methodology employed.
151A single crystal of the major isomer of 7e obtained in the Ugi
152reduction sequence (Table 1, entry 6) allowed X-ray diﬀraction
153analysis identiﬁcation of its absolute conﬁguration as (αS,3R),
154 f4with the expected P-conformation of benzodiazepine (Figure
155 f44). This result, coupled with the 1H NMR spectra, allowed the
156assignment of absolute conﬁguration of the new benzodiaze-
157pines synthesized. On the one hand, the proton signal at C3
158around 5 ppm conﬁrms the pseudoaxial arrangement of the
159larger substituent, and the axial disposition of the C3 proton
160would shift this signal to a lower chemical shift due to the
161shielding cone of the benzene ring.23 On the other hand, the
162signal of this proton in the unlike stereoisomer appears at a
163lower frequency (around 0.2 ppm) than the same proton in the
164like stereoisomer.
165We observed that the reduction of the nitro-Ugi adduct
166followed by intramolecular cyclization produced the 1,4-
167benzodiazepin-5-ones with an α,3-unlike stereochemical
168relationship, while the Ugi/Staudinger/aza-Wittig sequence
169aﬀorded a like relative conﬁguration.
170The diﬀerent reaction mechanism for each cyclization
171methodology employed could explain the diﬀerent stereo-
172chemical outcomes in each case, a tandem [2 + 2]
173cycloaddition between the phosphazene and the carbonyl
174group in the aza-Wittig reaction24 and a nucleophilic25 or
175radical26 addition of the nitrogen to the C3-position of the
176acrylamide enol Ugi adduct in the reduction cyclization
177sequence. Trying to conﬁrm that, we decided to reduce the
178azide group using a similar methodology to that employed in
179the reduction of the nitro group. Thus, a mixture of azide Ugi
180adduct 5a (1 equiv) and stannous chloride (1.5 equiv) in
181ethanol was stirred at room temperature for 1 h to yield the
182benzodiazepine 7a.27 The reduction took place eﬃciently
183(chemical yield of 74%), and as expected, the stereochemical
184result was similar to that obtained with the nitro derivative with
185the same sense (unlike relative conﬁguration), although worse
186diatereoselectivity (15:85 vs 5:95), supporting the importance
187of the cyclization methodology chosen.
188Thus, although the Ugi reduction methodology has some
189chemical advantages over the Ugi/Staudinger/aza-Wittig (more
190ecofriendly, simple, and scalable methodology), from a
191stereochemical point of view, both methods are complemen-
192tary. Depending on the preferred conﬁguration of C3 and,
193therefore, on the preferred conformation of the benzodiazepine
194system, the methodology employed should be diﬀerent.
195In conclusion, we have demonstrated the versatility of the
196Ugi/postcondensation sequence in the synthesis of enantiopure
1971,4-benzodiazepin-3-ones. The conﬁguration of the new
198stereogenic center could be controlled by the methodology
199employed because the diastereoselectivity of the reaction is
200highly dependent on the cyclization step. The importance of
201these methodologies is illustrated by the selective super-
Table 1. Diastereoselective Synthesis of 1,4-Benzodiazepin-
5-ones from Ugi/Cyclization Sequences
entry 1 2 3 5/6a (%) 7 (%)b drc (l:u)d
1 1a 2a 3a 5a (69) 7af (80) 84:16e
2 1b 2a 3a 5b (61) 7bf (65) 70:30
3 1c 2a 3a 5c (65) 7cf (71) 81:19
4 1d 2a 3a 5d (72) 7df (88) 90:10
5 1e 2a 3a 6a (80) 7ag (87) 5:95e
6 1e 2b 3a 6b (70) 7eg (83) 7:93
7 1e 2a 3b 6c (75) 7fg (85) 4:96
8 1e 2a 3c 6d (75) 7gg (88) 1:99
9 1f 2a 3a 6e (73) 7hg (86) 3:97
10 1g 2a 3a 6f (76) 7ig (88) 2:98
aUgi adducts are obtained exclusively as enol tautomers, as shown by
NMR spectra. bIsolated yields for the major diastereomer.
cDetermined by 1H NMR analysis of the crude reaction mixtures.
dThe l(αS,3S):u(αS,3R) assigned on the basis of X-ray diﬀraction of
major isomer of 7e. eIdentical ratio is obtained using (R)-α-
methylbenzyl amine as chiral source (l(αR,3R):u(αR,3S)). fFollowing
the Staudinger/aza-Wittig methodology. gFollowing the reduction/
cyclization methodology.
Figure 4. X-ray diﬀraction structure of 1,4-benzodiazepin-3one
(αS,3R)-7e, the major isomer in the Ugi/reduction sequence.
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202 imposition of benzodiazepine enantiomers with β-turn motifs
203 (types I and II′ for 3R stereoisomers and types I′ and II for 3S
204 stereoisomers), which makes these complementary stereo-
205 selective methods potentially useful in the development of new
206 drugs.
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306Org. Chem. 2014, 79, 5163.
(26) 307The radical addition is a plausible mechanism which could
308explain the diﬀerent stereochemical result. Some references about
309nitrogen-centered radical reactions: (a) Zard, S. Z. Chem. Soc. Rev.
3102008, 37, 1603. (b) Musacchio, A. J.; Nguyen, L. Q.; Beard, G. H.;
311Knowles, R: R. J. Am. Chem. Soc. 2014, 136, 12217.




Org. Lett. XXXX, XXX, XXX−XXX
D
